The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Moody's Upgrades ProHealth Care to Aa3 on 562 Days Cash

Moody's Ratings upgraded the credit rating of Waukesha, Wisconsin-based ProHealth Care to 'Aa3' on Oct. 19, according to Becker's Hospital Review. The agency pointed to very strong financial performance and liquidity that sits well above peers, with the system reporting 562 days cash on hand.

Moody's named disciplined management as the central driver of the upgrade. That discipline has helped ProHealth reduce debt and strengthen both its leverage and debt affordability, the agency said. For a nonprofit health system, a higher rating lowers borrowing costs, an advantage that compounds when systems finance new facilities, technology, and expansion.

The upgrade stands out at a moment when many hospitals are still absorbing elevated labor costs and thin margins. ProHealth's deep cash reserves give it a cushion most peers lack and more room to invest without taking on expensive debt. For operators and investors, the move is a reminder that balance-sheet strength, not just revenue growth, is what rating agencies reward.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.